Patents by Inventor Anthony W. Opipari

Anthony W. Opipari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230106899
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having (i) one or both of (i) decreased TREX1 level and/or activity, and (ii) increased cGAS/STING signaling pathway activity, e.g., as compared to a reference level, and/or (ii) an elevated level of cGAMP in a serum or tumor sample of the subject as compared to a reference level.
    Type: Application
    Filed: June 19, 2020
    Publication date: April 6, 2023
    Inventors: Gary Glick, Anthony W. Opipari, Jr., Hans Martin Seidel
  • Publication number: 20150031068
    Abstract: The present invention relates to methods and compositions for detecting immune system activation and/or the presence of an immune disorder in a patient. More particularly, methods and compositions for detecting immune system activation and/or the presence of an immune disorder in a patient by detecting, for example, the concentration of certain metabolites of 13C-labeled glutamine, 13C-labeled palmitate, and/or 13C-labeled glucose.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 29, 2015
    Applicant: Lycera Corporation
    Inventors: Gary D. Glick, Anthony W. Opipari, JR., Laszlo G. Boros
  • Patent number: 8809323
    Abstract: Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: August 19, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari, Jr.
  • Patent number: 8722667
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: May 13, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari
  • Publication number: 20140038947
    Abstract: Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.
    Type: Application
    Filed: May 17, 2013
    Publication date: February 6, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Gary D. Glick, Anthony W. Opipari, JR.
  • Publication number: 20130190300
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
    Type: Application
    Filed: December 17, 2012
    Publication date: July 25, 2013
    Applicant: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari
  • Patent number: 8415343
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: April 9, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari
  • Patent number: 7572788
    Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 11, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari
  • Publication number: 20090012065
    Abstract: Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of the following structures: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drug screening assays and other diagnostic methods.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 8, 2009
    Inventors: Gary D. Glick, Anthony W. Opipari, JR.
  • Patent number: 7220739
    Abstract: Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of the following structures: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drug screening assays and other diagnostic methods.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: May 22, 2007
    Assignee: Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari, Jr.
  • Patent number: 7125866
    Abstract: Benzodiazepinc compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures (I) or (II): wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: October 24, 2006
    Assignee: Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari, Jr.
  • Publication number: 20030119029
    Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
    Type: Application
    Filed: August 13, 2002
    Publication date: June 26, 2003
    Applicant: Regents of the University of Michigan
    Inventors: Gary D. Glick, Anthony W. Opipari
  • Publication number: 20010016583
    Abstract: Benzodiazepine compounds, and methods for using those compounds are provided.
    Type: Application
    Filed: January 22, 2001
    Publication date: August 23, 2001
    Inventors: Gary D. Glick, Anthony W. Opipari